Dicot AB presents Interim report January - March 2023

First quarter, January - March 2023

• Net sales amounts to KSEK 0 (0)
• Earnings after financial items amounts to KSEK -9,944 (-9,346)
• Earnings per share amounts to SEK -0.03 (-0.09)

"When I saw the outcome, that the issue was subscribed to 110%, it was a splendid acknowledgement that the market seems to shares our strong belief in the company", says Elin Trampe, CEO.

Significant events during the quarter

• The rights issue in January, which was 110% oversubscribed, together with a directed issue to guarantors, yielded a total of SEK 50.1 million after costs. At the same time, the share capital was reduced.
• Clinical Trial Consultants was contracted to conduct Dicot's phase 1 study and Thermo Fischer Scientific to manufacture the study drug.
• The Swedish Medical Products Agency responded positively to Dicot's proposed study design for clinical phase 1.
• Dicot proceeded with the patent application for the oral formulation to be used in phase 1.
• Study results of the mode of action were presented at the European Society for Sexual Medicine.

Significant events after the quarter

• The preclinical toxicology program was completed with good results and good safety profile.
• Clinical start for phase 1 study booked in August at Clinical Trial Consultants.
• The Nomination Committee proposes Jan-Eric Österlund as a new board member. Mats Silvander is recruited to the new role of Chief Technical Officer.